Ismayil Ahmet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11669616/publications.pdf

Version: 2024-02-01

34 papers	1,754 citations	361413 20 h-index	377865 34 g-index
35 all docs	35 docs citations	35 times ranked	2745 citing authors

#	Article	IF	Citations
1	Emergence of heartbeat frailty in advanced age I: perspectives from life-long EKG recordings in adult mice. GeroScience, 2022, 44, 2801-2830.	4.6	8
2	Overexpression of a Neuronal Type Adenylyl Cyclase (Type 8) in Sinoatrial Node Markedly Impacts Heart Rate and Rhythm. Frontiers in Neuroscience, 2019, 13, 615.	2.8	38
3	Long-term low dose dietary resveratrol supplement reduces cardiovascular structural and functional deterioration in chronic heart failure in rats. Canadian Journal of Physiology and Pharmacology, 2017, 95, 268-274.	1.4	29
4	Mammalian Î³2 AMPK regulates intrinsic heart rate. Nature Communications, 2017, 8, 1258.	12.8	43
5	Deterioration of autonomic neuronal receptor signaling and mechanisms intrinsic to heart pacemaker cells contribute to ageâ€associated alterations in heart rate variability inÂvivo. Aging Cell, 2016, 15, 716-724.	6.7	44
6	A Rat Carotid Balloon Injury Model to Test Anti-vascular Remodeling Therapeutics. Journal of Visualized Experiments, 2016, , .	0.3	5
7	Vessel Ultrasound Sonographic Assessment of Soluble Receptor for Advanced Glycation End Products Efficacy in a Rat Balloon Injury Model. Current Therapeutic Research, 2014, 76, 110-115.	1.2	1
8	Synchronization of sinoatrial node pacemaker cell clocks and its autonomic modulation impart complexity to heart beating intervals. Heart Rhythm, 2014, 11, 1210-1219.	0.7	62
9	The N-glycoform of sRAGE is the key determinant for its therapeutic efficacy to attenuate injury-elicited arterial inflammation and neointimal growth. Journal of Molecular Medicine, 2013, 91, 1369-1381.	3.9	17
10	Chronic Administration of Small Nonerythropoietic Peptide Sequence of Erythropoietin Effectively Ameliorates the Progression of Postmyocardial Infarctionâ€“Dilated Cardiomyopathy. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 446-456.	2.5	20
11	Acute hemodynamic effects of erythropoietin do not mediate its cardioprotective properties. Biology Open, 2012, 1, 1049-1053.	1.2	1
12	Fumarate Is Cardioprotective via Activation of the Nrf2 Antioxidant Pathway. Cell Metabolism, 2012, 15, 361-371.	16.2	231
13	Did Clinical Trials in Which Erythropoietin Failed to Reduce Acute Myocardial Infarct Size Miss a Narrow Therapeutic Window?. PLoS ONE, 2012, 7, e34819.	2.5	16
14	Fenoterol Enantiomers Do Not Possess Beneficial Therapeutic Properties of Their Racemic Mixture in the Rat Model of Post Myocardial Infarction Dilated Cardiomyopathy. Cardiovascular Drugs and Therapy, 2012, 26, 101-108.	2.6	1
15	Î²2 AR Agonists in Treatment of Chronic Heart Failure: Long Path to Translation. Journal of Molecular and Cellular Cardiology, 2011, 51, 529-533.	1.9	59
16	Effects of calorie restriction on cardioprotection and cardiovascular health. Journal of Molecular and Cellular Cardiology, 2011, 51, 263-271.	1.9	78
17	A Small Nonerythropoietic Helix B Surface Peptide Based upon Erythropoietin Structure Is Cardioprotective against Ischemic Myocardial Damage. Molecular Medicine, 2011, 17, 194-200.	4.4	50
18	Cardioprotective effect of intermittent fasting is associated with an elevation of adiponectin levels in rats. Journal of Nutritional Biochemistry, 2010, 21, 413-417.	4.2	104

#	Article	IF	Citations
19	Chronic Alternate-Day Fasting Results in Reduced Diastolic Compliance and Diminished Systolic Reserve in Rats. Journal of Cardiac Failure, 2010, 16, 843-853.	1.7	29
20	Blueberry-Enriched Diet Protects Rat Heart from Ischemic Damage. PLoS ONE, 2009, 4, e5954.	2.5	54
21	Survival and Cardioprotective Benefits of Long-Term Blueberry Enriched Diet in Dilated Cardiomyopathy Following Myocardial Infarction in Rats. PLoS ONE, 2009, 4, e7975.	2.5	28
22	Cardioprotective and Survival Benefits of Long-Term Combined Therapy with Î²2 Adrenoreceptor (AR) Agonist and Î²1 AR Blocker in Dilated Cardiomyopathy Postmyocardial Infarction. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 491-499.	2.5	69
23	Therapeutic Angiogenesis Induced by Injecting Hepatocyte Growth Factor in Ischemic Canine Hearts. Surgery Today, 2005, 35, 855-860.	1.5	13
24	Pharmacological Stimulation of Î² 2-adrenergic Receptors (Î² 2AR) Enhances Therapeutic Effectiveness of Î² 1AR Blockade in Rodent Dilated Ischemic Cardiomyopathy. Heart Failure Reviews, 2005, 10, 289-296.	3.9	52
25	Cardioprotection by Intermittent Fasting in Rats. Circulation, 2005, 112, 3115-3121.	1.6	202
26	Beneficial Effects of Chronic Pharmacological Manipulation of Î²-Adrenoreceptor Subtype Signaling in Rodent Dilated Ischemic Cardiomyopathy. Circulation, 2004, 110, 1083-1090.	1.6	112
27	Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Annals of Thoracic Surgery, 2003, 75, 1283-1287.	1.3	35
28	Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 11612-11617.	7.1	282
29	Gene transfection of hepatocyte growth factor attenuates cardiac remodeling in the canine heart: A novel gene therapy for cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2002, 124, 957-963.	0.8	31
30	Cardioprotective effect of diadenosine tetraphosphate (AP4A) cardioplegia in isolated rat hearts. Heart and Vessels, 2000, 15, 30-34.	1.2	4
31	Diadenosine tetraphosphate (AP4A) mimics cardioprotective effect of ischemic preconditioning in the rat heart: contribution of K ATP channel and PKC. Basic Research in Cardiology, 2000, 95, 235-242.	5.9	14
32	Myocardial protection using diadenosine tetraphosphate with pharmacological preconditioning. Annals of Thoracic Surgery, 2000, 70, 901-905.	1.3	5
33	CARDIOPROTECTIVE EFFECT OF DIADENOSINE TETRAPHOSPHATE (AP4A) PRESERVATION IN HYPOTHERMIC STORAGE AND ITS RELATION WITH MITOCHONDRIAL ATP-SENSITIVE POTASSIUM CHANNELS. Transplantation, 2000, 69, 16.	1.0	10
34	The effects of a new ultra-short-acting Î²-adrenergic blocker, ONO-1101, on cardiac function during and after cardiopulmonary bypass. Surgery Today, 1999, 29, 248-254.	1.5	7